

Resource Summary Report

Generated by [ASWG](#) on Aug 2, 2026

European Medicines Agency

RRID:SCR_011215

Type: Tool

Proper Citation

European Medicines Agency (RRID:SCR_011215)

Resource Information

URL: <http://www.ema.europa.eu/>

Proper Citation: European Medicines Agency (RRID:SCR_011215)

Description: An agency responsible for the evaluation and supervision of medicines developed by pharmaceutical companies for use in the European Union. Its main responsibility is the protection and promotion of public and animal health through the evaluation and supervision of medicines for human and veterinary use. The Agency also plays a role in stimulating innovation and research in the pharmaceutical sector. The Agency gives scientific advice and other assistance to companies for the development of new medicines. It publishes guidelines on quality-, safety- and efficacy-testing requirements. A dedicated SME Office provides special assistance to small and medium-sized enterprises.

Abbreviations: EMA

Synonyms: EU Medicines Agency

Resource Type: nonprofit organization

Resource Name: European Medicines Agency

Resource ID: SCR_011215

Alternate IDs: grid.452397.e, Wikidata: Q130146, nif-0000-30532

Alternate URLs: <https://ror.org/01z0wsw92>

Record Creation Time: 20220129T080303+0000

Record Last Update: 20260801T190421+0000

Ratings and Alerts

No rating or validation information has been found for European Medicines Agency.

No alerts have been found for European Medicines Agency.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 347 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#).

Łabędź-Masłowska A, et al. (2025) Evaluation of the Safety and Regenerative Potential of Human Mesenchymal Stem Cells and Their Extracellular Vesicles in a Transgenic Pig Model of Cartilage-Bone Injury In Vivo - Preclinical Study. Stem cell reviews and reports, 21(4), 1075.

Panaitescu-Damian A, et al. (2025) Addressing Pancreatic Exocrine Insufficiency and the Impact of Pancreatic Enzyme Replacement Therapy Shortages in Europe. United European gastroenterology journal, 13(10), 2090.

Patrinos GP, et al. (2025) Systematic analysis of the pharmacogenomics landscape towards clinical implementation of precision therapeutics in Greece. Human genomics, 19(1), 11.

Siebenhüner AR, et al. (2025) Impact of multikinase inhibitors in reshaping the treatment of advanced gastroenteropancreatic neuroendocrine tumors. Endocrine-related cancer, 32(6).

Bonomini A, et al. (2025) Antiviral strategies against influenza virus: an update on approved and innovative therapeutic approaches. Cellular and molecular life sciences : CMLS, 82(1), 75.

Giraudet R, et al. (2025) Immunogenicity of single-chain antibodies: germlining of a VHH lowers T-cell activation from epitopes in FR2 and CDR regions. mAbs, 17(1), 2571406.

O'Connor D, et al. (2025) Prediction and characterisation of the human B cell response to a heterologous two-dose Ebola vaccine. Nature communications, 16(1), 6331.

De Brouhoven I, et al. (2025) Trametinib as a targeted treatment in cardiac and lymphatic presentations of Noonan syndrome. Frontiers in pediatrics, 13, 1475143.

Essink SCM, et al. (2025) Risk Minimisation Measures of Advanced Therapy Medicinal Products Authorised in the EU Between 2009 and 2023: A Cross-Sectional Study. Drug safety, 48(9), 1005.

Oosterhof P, et al. (2025) Optimising antiretroviral therapy through a proactive treatment algorithm: a cost-effective strategy in Dutch healthcare for people with HIV. The Journal of

antimicrobial chemotherapy, 80(6), 1656.

Liu R, et al. (2025) Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from advanced solid tumors. *Experimental hematology & oncology*, 14(1), 136.

Alves PCG, et al. (2025) Awareness of risk when prescribing and taking combined hormonal contraceptives (CHCs): a qualitative study with women and health professionals in three European countries. *BMJ open*, 15(3), e084735.

Sauer J, et al. (2025) The sodium/glucose cotransporter 2 inhibitor empagliflozin is a pharmacological chaperone of cardiac Nav1.5 channels. *American journal of physiology. Heart and circulatory physiology*, 329(3), H680.

Spagnolo F, et al. (2025) Dataset of SARS-CoV-2 spike protein receptor binding domain variants in complex with antigen-binding fragments targeting COVID-19 vaccine-referenced variants. *Data in brief*, 58, 111291.

Habibi A, et al. (2025) Protease-activated receptors in vascular smooth muscle cells: a bridge between thrombo-inflammation and vascular remodelling. *Cell communication and signaling : CCS*, 23(1), 57.

Kaur A, et al. (2025) Machine learning approach for optimizing usability of healthcare websites. *Scientific reports*, 15(1), 14450.

Zhang Q, et al. (2025) Antimicrobial peptides: from discovery to developmental applications. *Applied and environmental microbiology*, 91(4), e0211524.

Ma B, et al. (2024) Combining metabolomics and transcriptomics to reveal the potential medicinal value of rare species *Glycyrrhiza squamulose*. *Heliyon*, 10(10), e30868.

Shi Y, et al. (2024) The Real-World Effectiveness and Tolerability of a Soothing Cream Containing the Postbiotic *Aquaphilus dolomiae* Extract-G2 for Skin Healing. *Dermatology and therapy*, 14(3), 697.

Mou Z, et al. (2024) Quantitative Structure-Activity Relationship Models to Predict Cardiac Adverse Effects. *Chemical research in toxicology*, 37(12), 1924.